Gilead is committed to using its virology expertise to advance HIV treatment and prevention to help end the epidemic. Since 2010, the company has partnered with Emory University in Atlanta to launch AIDSVu – an online mapping tool that visualizes granular data
This year's Biomedical HIV Prevention Summit in Atlanta emphasized the importance of advancing prevention in the U.S. South, a region disproportionately impacted by HIV.
We’re focused on driving innovation in virology, oncology and immunology – and that includes investing in world-class science to change the way cancer is treated.
At Gilead, putting people first is central to all we do. That’s why we’re proud to be recognized as a responsible company by patient advocacy groups representing more than 70 countries.
As a medical oncologist who has practiced in three different countries, Dr. Maria Alice Franzoi is well acquainted with various healthcare systems and has a keen interest in researching patient-centered care models and innovative digital healthcare tools.
We’re proud to once again be ranked in the top five of Americas Most Just companies in biopharma. The honor reflects our ongoing commitment to operate responsibly and empower our employees to help create a healthier world for all.
In recognition of Women's History Month, our Identity + Innovation spotlight features Devi SenGupta. Hear how Devi's background has shaped her approach to developing new medicines and to bringing Gilead closer to a cure for HIV.
Lauren Huffmaster received a late-stage metastatic breast cancer (mBC) diagnosis in 2015 and soon discovered there wasn’t a lot information to help explain to her young children what she was going through.
Each scientific discovery gets us one step closer to our shared goal of ending the HIV epidemic. As a leader in HIV treatment and prevention, we’ll continue to build on our legacy and create innovative solutions to address the diverse needs of all people affected by HIV.
Congratulations to Taiyin Yang, EVP, Pharmaceutical Development and Manufacturing, for being elected to the 2022 class of the National Academy of Engineering.
While as a company, we have unsurprisingly always taken a clear stance against stigma, Gilead has prioritized its grant-making to support organizations working at the community level in recent years.
Gilead has launched a first-of-its-kind educational partnership with historically Black colleges and universities (HBCUs) and Hispanic-Serving Institutions (HSIs).
Most people are familiar with the hepatitis B (HBV) and hepatitis C (HCV) viruses that attack the liver. But not many have heard of hepatitis D (HDV), the most severe form of viral hepatitis
Dr. Porscha Showers’ route to health sciences wasn’t always a sure thing. Porscha, who grew up in Louisiana, wanted to become an attorney – despite having a mother who worked as a registered nurse and a father who was a laboratory chemist.
In the second installment of our “Inside the Innovation” series, Gilead’s Ken Kent and Monica Tijerina discuss our patient-focused approach to developing medicines and the importance of including diverse voices throughout the process.
Gilead HIV Policy Directors Dan Murphy and Pema McGuinness recently developed a series of policy papers that warn of the consequences if governments fail to take steps to prioritize and invest in HIV.
As the ninth of 13 children, Dr. Carmen J. Walters grew up in New Orleans, where her father built houses during the day and worked at the railroad at night, and her mother did a variety of jobs, such as cooking for local schools.
Gilead’s Corporate Social Responsibility (CSR) Report provides an overview of the work the company is doing around the world to improve the lives of...